Properties
What is it?
RINOMARIS INTENSIVE Composition: Active substance: Ipratropium bromide; xylometazoline hydrochloride; 1ml contains 0.6mg ipratropium bromide monohydrate and 0.5mg xylometazoline hydrochloride; Excipients: disodium edetate, purified seawater, glycerin 85%, hydrochloric acid and sodium hydroxide (to adjust pH), purified water. Indications: Symptomatic treatment of nasal congestion and rhinorrhea during respiratory diseases. Contraindications: Hypersensitivity to any component of the preparation. Known hypersensitivity to atropine or similar agents, e.g., hyoscyamine, scopolamine. Following surgery on the dura mater of the brain, e.g., transsphenoidal hypophysectomy or other transnasal surgeries; acute coronary diseases, coronary asthma, hyperthyroidism; glaucoma; dry rhinitis; pediatric age (under 18 years). Interactions with other drugs and other types of interactions: Monoamine oxidase inhibitors (MAO inhibitors): Administration of the preparation is not recommended with MAO inhibitors and within 2 weeks after the end of treatment, as arterial blood pressure may increase significantly. Sympathomimetic preparations cause the release of catecholamines, leading to intensive norepinephrine release, which in turn exhibits a vasoconstrictive effect, resulting in increased arterial blood pressure. If the increase in blood pressure is critical, RINOMARIS INTENSIVE should be discontinued and symptomatic treatment initiated. Tricyclic and tetracyclic antidepressants: Administration of RINOMARIS INTENSIVE is not recommended with tricyclic and tetracyclic antidepressants and within 2 weeks after the end of treatment, as an enhancement of the sympathomimetic effect of xylometazoline is expected. When taken with other anticholinergic preparations, an enhancement of the anticholinergic effect may be observed. The above interactions were studied for each active substance of RINOMARIS INTENSIVE separately, not in combination. Official studies of interactions with other drugs have not been conducted. Special features of use: RINOMARIS INTENSIVE should be used with caution in patients prone to developing angle-closure glaucoma, prostatic hypertrophy, and bladder neck stenosis. The preparation should not come into contact with the eyes and the area around the eyes. If the preparation gets into the eyes, the following reactions are expected: temporary blurred vision, eye irritation, pain, redness. Angle-closure glaucoma may be complicated. Patients should be instructed to rinse with cold water if the preparation gets into the eyes. If eye pain or blurred vision occurs, consult a doctor. The preparation should be used with caution in cases of nosebleeds (e.g., elderly patients), probability of paralytic ileus, and in patients with cystic fibrosis. RINOMARIS INTENSIVE should be used with caution in patients who are sensitive to adrenergic preparations, as sleep disturbances, dizziness, tremors, cardiac arrhythmias, or increased blood pressure may occur. Caution is advised in patients with hyperthyroidism, diabetes mellitus, arterial hypertension, cardiovascular diseases, or pheochromocytoma. Sudden hypersensitivity reactions, including urticaria, angioneurotic edema, rash, bronchospasm, laryngeal edema, anaphylactic reactions, may occur. Reporting suspected adverse reactions to the doctor after the registration of the preparation is very important, as it allows for continued monitoring of the benefit-risk ratio of the preparation.